NCT04732897

Brief Summary

Hallux Valgus (HV) is a lateral deviation of the big toe. HV is a deformity of the forefoot centered on the 1st radius (1st metatarsal and big toe). This deformation is characterized by:

  • a big toe (hallux) deviated outwards (valgus greater than 12 °)
  • a first metatarsal moved medially (varus) (angle M1 / M2\> 10 °). We also note the existence of an exostosis formed by the apex of the angle between the 1st metatarsal deviated inwards and the big toe deported outwards. This exostosis corresponds to the head of the 1st metatarsal. In addition to the pain and the unaesthetic nature induced by this deviation, the modifications of the skeletal axes of the foot cause disorders of its function but also of the joints of the lower limb during standing, walking and running. Axis defects of the lower limbs in varum or valgum also cause deformities in the rearfoot, midfoot and forefoot. There is no non-surgical curative treatment for this deformity. Different conservative treatment options have been offered for first-line treatment, including different types of physiotherapy, wearing rigid insoles or splints. Wearing rigid insoles is indicated to "counter" the valgic pressure, thereby reducing pain and high plantar pressure, in patients with HV. Their hardness, expressed in SHORE units, must be greater than 65. By countering the valgic pressure (rearfoot and midfoot), the rigid soles make it possible to contain the development of deformation and stabilize the axis of the first spoke. The speed of hallux deformation is therefore greatly reduced if the soles are worn diligently. But there is little or no impact on the correction of the deformity, but it is stabilized as it is without rapid and major worsening. Indeed, soles with a hardness greater than or equal to 65 SHORE make it possible to avoid the valgum of the hindfoot and midfoot under load and when walking. Wearing a dynamic splint was studied in a recently published prospective randomized study conducted between 2011 and 2013. This study, concluding that the dynamic splint is not effective in reducing the angle of deformation of the HV, nevertheless shows the reduction in pain during walking and running. The limits of the study lie in the pace of wearing the splint, left to the discretion of patients, during their rest period, and in the duration of the operation, which is not precisely described.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
6

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 26, 2021

Completed
6 days until next milestone

First Posted

Study publicly available on registry

February 1, 2021

Completed
3 months until next milestone

Study Start

First participant enrolled

April 22, 2021

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 25, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 25, 2022

Completed
Last Updated

July 22, 2022

Status Verified

July 1, 2022

Enrollment Period

9 months

First QC Date

January 26, 2021

Last Update Submit

July 19, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change from baseline M1 / P1 angle at day 75 measured by weightbearing foot radiograph

    M1 / P1 angle measured before and after intervention

    radiograph between day 0 less than 6 months and day 0 and radiograph at day 75

Secondary Outcomes (8)

  • Variation of the M1 / M2 angle measured by weightbearing foot radiograph

    radiograph between day 0 less than 6 months and day 0 and radiograph at day 75

  • Variation of the M1 / P1 and M1/M2 angle measured by weightbearing foot radiograph at long time

    radiograph at day 75 and at month 6 and month 12

  • 12-month surgery rate

    month 12

  • Quality of life measured by the American Orthopedic Foot and Ankle Society score

    day 0, day 75, month 6 and month 12

  • Quality of life measured by the Foot Function Index score

    day 0, day 75, month 6 and month 12

  • +3 more secondary outcomes

Study Arms (2)

Control arm

NO INTERVENTION

wearing made-to-measure soles with SHORE greater than or equal to 65 (standard of care)

Interventional arm

EXPERIMENTAL

wearing made-to-measure soles with SHORE greater than or equal to 65 + dynamic dressing of the joint

Procedure: dynamic dressing

Interventions

Dynamic dressing is made by bandages of the foot with gauze pad, stretchable adhesive tape and elastic compression band

Interventional arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • hallux valgus on at least one foot theoretically requiring surgical management within 12 months
  • reducible hallux valgus
  • beneficiary of a social security scheme
  • informed of the study and signed informed consent form

You may not qualify if:

  • History of hallux valgus correction surgery on the affected foot
  • History of traumatic lesion of the M1-P1 metatarsophalangeal joint of the affected foot
  • Skin pathology limiting or contraindicating the possibility of dressings according to the judgment of the investigator (eg dyshidrotic eczema, psoriasis or other problematic skin damage located in the foot)
  • Acute bursitis
  • Clinical and / or radiological stage 1 or more osteoarthritis according to the criteria of Kellgren and Lawrence
  • Non-stabilized diabetes and / or diabetes with micro / macrovascular complications
  • Patients with neuropathy
  • History of gout
  • History of rheumatic pathology
  • Obliterating arteriopathy of the lower limbs of stage II or more according to the classification of Leriche and Fontaine
  • Pregnant woman
  • Patients under tutorship or curatorship
  • Patients under legal protection
  • Patients who do not understand French

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Centre Hospitalier Annecy Genevois

Metz-Tessy, 74374, France

Location

MeSH Terms

Conditions

Hallux Valgus

Condition Hierarchy (Ancestors)

Foot DeformitiesMusculoskeletal Diseases

Study Officials

  • Guy Allamel, PhD

    CH Annecy Genevois

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Open-label randomized trial
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 26, 2021

First Posted

February 1, 2021

Study Start

April 22, 2021

Primary Completion

January 25, 2022

Study Completion

January 25, 2022

Last Updated

July 22, 2022

Record last verified: 2022-07

Locations